United States securities and exchange commission logo





                            April 7, 2022

       Michael Shleifer
       Chief Executive Officer
       Biotech Acquisition Company
       545 West 25th Street, 20th Floor
       New York, NY 10001

                                                        Re: Biotech Acquisition
Company
                                                            Amendment No. 1 to
Registration Statement on Form S-4
                                                            Filed April 4, 2022
                                                            File No. 333-263577

       Dear Dr. Shleifer:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our March
25, 2022 letter.

       Amendment No. 1 to Form S-4 filed April 4, 2022

       What happens if the Minimum Cash Condition is not met?, page xx

   1.                                                   We note your response
to our prior comment 2 and your newly added disclosure that BAC
                                                        may seek to obtain
additional financing to meet the Minimum Cash Condition in the event
                                                        the condition is not
waived. Please advise us how you intend to communicate the terms of
                                                        any additional
financing to shareholders if such event occurs.
       BAC's Board of Directors' Reasons for the Business Combination, page 121

   2.                                                   We note your response
to our prior comment 10 and your newly added disclosure on page
                                                        122 that the BAC Board
also considered "various industry and financial data and materials
                                                        provided by management
and Blade..." Please further revise your disclosure to discuss the
 Michael Shleifer
Biotech Acquisition Company
April 7, 2022
Page 2
      substance of these materials so that investors may understand what
specifically was
      considered by the Board in arriving at its decision regarding the
transaction.
       You may contact Ibolya Ignat at 202-551-3636 or Kevin Vaughn at
202-551-3494 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Dillon Hagius at 202-551-7967 or Laura Crotty at 202-551-7614 with any
other
questions.



                                                          Sincerely,
FirstName LastNameMichael Shleifer
                                                          Division of
Corporation Finance
Comapany NameBiotech Acquisition Company
                                                          Office of Life
Sciences
April 7, 2022 Page 2
cc:       Richard Baumann
FirstName LastName